Aethlon Medical
AEMD
12 hedge funds and large institutions have $155K invested in Aethlon Medical in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
240% more capital invested
Capital invested by funds: $45.6K → $155K (+$109K)
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
50% more funds holding
Funds holding: 8 → 12 (+4)
2.82% more ownership
Funds ownership: 1.7% → 4.51% (+2.8%)
Top Buyers
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$55.4K |
| 2 |
SC
Shay Capital
New York
|
+$32.1K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$30.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.66K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.04K |
Top Sellers
| 1 |
Citigroup
New York
|
-$91 |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$17 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $53.4K | +$55.4K | +24,364 | New |
|
|
IC
2
Ikarian Capital
Dallas,
Texas
| $31.5K | – | – | – |
|
|
SC
3
Shay Capital
New York
| $30.9K | +$32.1K | +14,124 | New |
|
|
XT
4
XTX Topco
George Town,
Cayman Islands
| $29.2K | +$30.3K | +13,342 | New |
|
5
Morgan Stanley
New York
| $4.48K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $3.53K | +$3.66K | +1,611 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $1.96K | +$2.04K | +895 | New |
|
8
Group One Trading
Chicago,
Illinois
| $31 | – | – | – |
|
9
BlackRock
New York
| $22 | – | – | – |
|
|
CIAM
10
Caitong International Asset Management
Hong Kong
| $18 | +$18 | +8 | New |
|
11
Wells Fargo
San Francisco,
California
| $6 | – | – | – |
|
|
DB
12
Danske Bank
Copenhagen K,
Denmark
| $2 | – | – | – |
|
|
13
Citigroup
New York
| – | -$91 | -33 | Closed |
|
|
14
Bank of America
Charlotte,
North Carolina
| – | -$17 | -6 | Closed |
|
AEMD Hedge Fund Activity: Q1 2026 in Review
12 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Aethlon Medical (AEMD) for Q1 2026, worth a combined $155K — up 240% from $45.6K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AEMD positions and 2 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $55.4K. The largest seller was Citigroup, exiting entirely with an estimated $91 sold.
- 12 institutional investors held Aethlon Medical (AEMD) as of Q1 2026, up from 8 in Q4 2025.
- Funds reported $155K of Aethlon Medical stock for Q1 2026, up 240% quarter-over-quarter.
- 6 funds opened new Aethlon Medical positions in Q1 2026 and 2 closed out, a net change of +4 holders.
- The largest Aethlon Medical buyer in Q1 2026 was Geode Capital Management, an estimated $55.4K added.
- The largest Aethlon Medical seller in Q1 2026 was Citigroup, an estimated $91 sold.
Based on aggregated 13F filings for Q1 2026.